28389374|t|A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1 -Mediated DNA Repair
28389374|a|BRCA1 associated protein1 (BAP1) is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A, and DNA repair. BAP1 mutations are frequent in malignant pleural mesothelioma (MPM). Our aim was to functionally characterize a newly identified isoform of BAP1 and investigate the effects of its expression on drug sensitivity in MPM. Expression of BAP1 isoforms was detected by quantitative polymerase chain reaction in MPM and normal mesothelium cell lines and tumor and nontumor samples. Histone H2A ubiquitination levels were analyzed by Western blot after acidic extraction of core histones. Subcellular localization of BAP1 isoforms was examined by immunofluorescence. MPM cell survival in response to poly(adenosine diphosphate-ribose) polymerase (PARP) and dual phosphoinositide 3-kinase (PI3K)- mammalian target of rapamycin (mTOR) inhibitors was analyzed by in vitro assays. We have identified a novel alternative splice isoform of BAP1 (BAP1Δ) that misses part of the catalytic domain. Cells transfected with BAP1Δ showed reduced deubiquitinating activity compared with full-length BAP1. The expression of BAP1Δ transcript is more abundant in nontumor than in tumor samples. MPM cell lines expressing more than 20% of BAP1Δ are more sensitive to olaparib (a PARP1 inhibitor) cytotoxicity, and this sensitivity is enhanced when olaparib treatment is combined with GDC0980 (a dual PI3K - mTOR inhibitor), which induces downregulation of BRCA1. These observations suggest that BAP1Δ does regulate DNA damage response and influences drug sensitivity. It might therefore be relevant to investigate whether patients with high expression of BAP1Δ may be responsive to PARP / PI3K - mTOR inhibitors.
28389374	8	34	BRCA1-Associated Protein-1	T116,T123	C1368335
28389374	35	42	Isoform	T116	C0597298
28389374	43	50	Affects	T077	C4054723
28389374	51	59	Response	T032	C0871261
28389374	63	81	Mesothelioma Cells	T191	C0025500
28389374	85	90	Drugs	T121	C0013227
28389374	91	100	Impairing	T169	C0221099
28389374	101	106	BRCA1	T116,T123	C1528558
28389374	117	127	DNA Repair	T045	C0012899
28389374	128	153	BRCA1 associated protein1	T116,T123	C1368335
28389374	155	159	BAP1	T116,T123	C1368335
28389374	166	182	tumor suppressor	T116,T123	C0597611
28389374	195	203	multiple	T081	C0439064
28389374	204	222	cellular processes	T043	C0007613
28389374	231	257	transcriptional regulation	T045	C1158770
28389374	259	281	chromatin modification	T045	C1156197
28389374	285	301	deubiquitinating	T044	C1157996
28389374	302	312	histone 2A	T116	C0147579
28389374	318	328	DNA repair	T045	C0012899
28389374	330	334	BAP1	T116,T123	C1368335
28389374	335	344	mutations	T045	C0026882
28389374	349	357	frequent	T079	C0332183
28389374	361	391	malignant pleural mesothelioma	T191	C0812413
28389374	393	396	MPM	T191	C0812413
28389374	403	406	aim	T078	C1947946
28389374	414	426	functionally	T169	C0205245
28389374	427	439	characterize	T080	C1521970
28389374	448	458	identified	T080	C0205396
28389374	459	466	isoform	T116	C0597298
28389374	467	474	of BAP1	T116,T123	C1368335
28389374	479	490	investigate	T169	C1292732
28389374	495	502	effects	T080	C1280500
28389374	510	520	expression	T045	C0017262
28389374	524	540	drug sensitivity	T032	C0237865
28389374	544	547	MPM	T191	C0812413
28389374	549	559	Expression	T045	C0017262
28389374	563	567	BAP1	T116,T123	C1368335
28389374	581	589	detected	T033	C0442726
28389374	593	631	quantitative polymerase chain reaction	T059	C2733022
28389374	635	638	MPM	T191	C0812413
28389374	643	649	normal	T080	C0205307
28389374	650	661	mesothelium	T024	C0086610
28389374	662	672	cell lines	T025	C0007600
28389374	677	682	tumor	T024	C0475358
28389374	687	703	nontumor samples	T024	C1292533
28389374	705	716	Histone H2A	T116,T123	C0019646
28389374	717	731	ubiquitination	T044	C1156207
28389374	732	738	levels	T080	C0441889
28389374	744	752	analyzed	T062	C0936012
28389374	756	768	Western blot	T059	C0949466
28389374	775	792	acidic extraction	T059	C0684295
28389374	796	809	core histones	T116	C2987130
28389374	811	822	Subcellular	T026	C3893246
28389374	823	835	localization	T169	C0475264
28389374	839	843	BAP1	T116,T123	C1368335
28389374	844	852	isoforms	T116	C0597298
28389374	857	865	examined	T033	C0332128
28389374	869	887	immunofluorescence	T059	C0079603
28389374	889	892	MPM	T191	C0812413
28389374	893	906	cell survival	T043	C0007620
28389374	910	918	response	T032	C0871261
28389374	922	967	poly(adenosine diphosphate-ribose) polymerase	T116,T126	C0032405
28389374	969	973	PARP	T116,T126	C0032405
28389374	984	1009	phosphoinositide 3-kinase	T116,T126	C0044602
28389374	1011	1015	PI3K	T116,T126	C0044602
28389374	1018	1047	mammalian target of rapamycin	T116,T126	C1307407
28389374	1049	1053	mTOR	T116,T126	C1307407
28389374	1055	1065	inhibitors	T121	C0014432
28389374	1070	1078	analyzed	T062	C0936012
28389374	1082	1097	in vitro assays	T062	C1515653
28389374	1107	1117	identified	T080	C0205396
28389374	1126	1152	alternative splice isoform	T116	C1720834
28389374	1156	1160	BAP1	T116,T123	C1368335
28389374	1162	1167	BAP1Δ	T028	C1332380
28389374	1193	1209	catalytic domain	T087	C0600499
28389374	1211	1216	Cells	T025	C0007634
28389374	1217	1228	transfected	T063	C0040669
28389374	1234	1239	BAP1Δ	T028	C1332380
28389374	1247	1254	reduced	T080	C0392756
28389374	1255	1280	deubiquitinating activity	T044	C1157996
28389374	1281	1289	compared	T052	C1707455
28389374	1307	1311	BAP1	T116,T123	C1368335
28389374	1317	1327	expression	T045	C0017262
28389374	1331	1336	BAP1Δ	T028	C1332380
28389374	1337	1347	transcript	T114	C1519595
28389374	1356	1364	abundant	T080	C2346714
28389374	1368	1376	nontumor	T024	C1292533
28389374	1400	1403	MPM	T191	C0812413
28389374	1404	1414	cell lines	T025	C0085983
28389374	1415	1425	expressing	T045	C0017262
28389374	1443	1448	BAP1Δ	T028	C1332380
28389374	1458	1467	sensitive	T169	C0332324
28389374	1471	1479	olaparib	T109,T121	C2316164
28389374	1483	1488	PARP1	T116,T126	C1567710
28389374	1489	1498	inhibitor	T121	C0014432
28389374	1500	1512	cytotoxicity	T049	C0596402
28389374	1523	1534	sensitivity	T169	C0332324
28389374	1538	1546	enhanced	T052	C2349975
28389374	1552	1560	olaparib	T109,T121	C2316164
28389374	1561	1570	treatment	T058	C3887704
28389374	1574	1582	combined	T080	C0205195
28389374	1588	1595	GDC0980	T121	C2984520
28389374	1604	1608	PI3K	T116,T126	C0044602
28389374	1611	1615	mTOR	T116,T126	C1307407
28389374	1616	1625	inhibitor	T121	C0014432
28389374	1634	1641	induces	T169	C0205263
28389374	1642	1656	downregulation	T044	C0013081
28389374	1660	1665	BRCA1	T116,T123	C1528558
28389374	1673	1685	observations	T062	C0302523
28389374	1699	1704	BAP1Δ	T028	C1332380
28389374	1710	1738	regulate DNA damage response	T043	C3270705
28389374	1743	1753	influences	T077	C4054723
28389374	1754	1770	drug sensitivity	T032	C0237865
28389374	1794	1802	relevant	T080	C2347946
28389374	1806	1817	investigate	T169	C1292732
28389374	1826	1834	patients	T101	C0030705
28389374	1840	1844	high	T080	C0205250
28389374	1845	1855	expression	T045	C0017262
28389374	1859	1864	BAP1Δ	T028	C1332380
28389374	1872	1882	responsive	T201	C0521982
28389374	1886	1890	PARP	T116,T126	C0032405
28389374	1893	1897	PI3K	T116,T126	C0044602
28389374	1900	1904	mTOR	T116,T126	C1307407
28389374	1905	1915	inhibitors	T121	C0014432